ISSN: 2169-0138
Donald Sikazwe
Feik School of Pharmacy
University of the Incarnate Word, USA
Dr. Sikazwe earned a PhD in Pharmaceutical Sciences from Florida A & M University. His dissertation, in the CNS area, focused on design, synthesis, characterization, and evaluation of dopaminereceptor antagonists as potential antipsychotics. He interned at Schering-Plough, and synthesized novel chemical templates for generating anti-inflammatory drug libraries. He then joined the Medicinal Chemistry Department at Virginia Commonwealth University (VCU) as a Kirschstein-NRSA Postdoctoral Research Fellow (2004 - 2006). His research at VCU involved rational design, synthesis and structural activity relationship (SAR) development of serotonin-6 receptor ligands for CNS disorders.Thereafter, he joined the Roskamp Institute (2006) and laterits spin-off biotech Archer Pharmaceuticals Inc. (2008) where he synthesized heterocyclic compounds for Alzheimer’s disease. In 20009, Dr. Sikazwe joined the Feik School of Pharmacy, San Antonio, TX, where he now teaches Medicinal Chemistry courses. He has authored several articles and is a holder of two patents.
Discovery of novel chemical agents for treating various disease states, in particular CNS disorders (Alzheimers, Schizophrenia, etc.).